8-K: IDEAYA Biosciences Announces Promising Clinical Data for IDE397 in MTAP-Deletion Cancers

IDEAYA Biosciences reports encouraging Phase 1 clinical data for IDE397, showing a 33% overall response rate in patients with MTAP-deletion urothelial and non-small cell lung cancer.

Summary

• IDEAYA Biosciences announced positive interim Phase 1 expansion data for IDE397, a potential first-in-class MAT2A inhibitor, in patients with MTAP-deletion urothelial cancer and non-small cell lung cancer (NSCLC).
• The data, from 27 evaluable patients, showed an overall response rate of approximately 33%, with one complete response and eight partial responses.
• The confirmed overall response rate was 40% in urothelial cancer, 38% in squamous NSCLC, and 22% in adenocarcinoma NSCLC.
• A disease control rate of 93% was observed, with 25 out of 27 patients achieving stable disease or better.
• The median duration of treatment is greater than 6.2 months, and the median time to response is approximately 2.7 months.
• A ctDNA molecular response rate of approximately 81% was observed, with 33% showing a deep 90% or greater ctDNA reduction.
• The drug demonstrated a favorable safety profile, with only 18% of patients experiencing a Grade 3 or higher drug-related adverse event and no drug-related serious adverse events.
• The company is planning to initiate a Phase 1/2 combination expansion of IDE397 with Trodelvy in MTAP-deletion urothelial cancer in Q4 2024.
• MTAP-deletion is prevalent in over 15% of NSCLC and over 25% of urothelial cancer, with an estimated annual incidence of 48,000 patients in the U.S.
• The company has activated over 35 clinical trial sites globally to enable rapid enrollment for the IDE397 Phase 2 monotherapy expansion.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for IDE397, with strong response rates and a favorable safety profile. The planned combination trial and large addressable market further contribute to a positive outlook.

Positives

• The overall response rate of 33% is promising for a heavily pre-treated patient population.
• The 40% confirmed overall response rate in urothelial cancer is particularly encouraging.
• The high disease control rate of 93% suggests a significant clinical benefit.
• The favorable safety profile of IDE397 is a positive sign for long-term dosing and combination development.
• The rapid and deep ctDNA molecular responses indicate the drug's potential efficacy.
• The planned combination trial with Trodelvy could further enhance treatment outcomes.
• The large addressable market for MTAP-deletion cancers presents a significant opportunity.

Negatives

• The median duration of response and median progression-free survival data are still immature.
• The response rate in adenocarcinoma NSCLC was lower at 22% compared to other subtypes.
• The data is based on an interim analysis and may change as the study progresses.
• The study is based on a small sample size of 27 evaluable patients.

Risks

• The clinical development of IDE397 is still in its early stages, and there are inherent risks in the drug development process.
• The regulatory approval process is uncertain, and there is no guarantee that IDE397 will be approved.
• The company faces challenges associated with manufacturing drug products and protecting its intellectual property.
• The company's ability to fund operations is dependent on its existing cash reserves.

Future Outlook

The company anticipates initiating the IDE397 and Trodelvy Phase 1/2 combination expansion in MTAP-deletion urothelial cancer in Q4 2024 and is focused on enrolling patients in the IDE397 Phase 2 monotherapy expansion in MTAP-deletion lung and bladder cancer.

Management Comments

• The company reported an overall response rate of approximately 33% (one complete response and eight partial responses by RECIST 1.1 evaluation).
• The company observed a disease control rate of 93%, including one complete response, eight partial responses and 16 stable disease by RECIST 1.1 evaluation.
• The company anticipates that the favorable AE profile and dosing convenience of a 30 mg QD tablet has the potential to enable long-term dosing and combination development.

Industry Context

This announcement is significant as there are currently no FDA-approved therapies for patients with MTAP-deletion solid tumors, highlighting a substantial unmet medical need. The positive results for IDE397 position it as a potential first-in-class treatment option in this space. The combination with Trodelvy also aligns with the industry trend of exploring combination therapies to improve patient outcomes.

Comparison to Industry Standards

• The reported overall response rate of 33% for IDE397 is competitive with other targeted therapies in similar cancer types, especially considering the heavily pre-treated patient population.
• For example, in urothelial cancer, checkpoint inhibitors have shown response rates in the 20-30% range in similar patient populations, making the 40% response rate in this study particularly notable.
• The disease control rate of 93% is also higher than what is typically seen with standard chemotherapy regimens in these advanced cancer settings.
• The favorable safety profile of IDE397 is also a positive differentiator, as many targeted therapies are associated with significant side effects.

Related Party Transactions

• The company has a Clinical Trial Collaboration and Supply Agreement with Gilead, where Gilead will supply Trodelvy for the combination trial.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical data.
• Patients with MTAP-deletion cancers may benefit from a new treatment option.
• Employees may be motivated by the positive results and the potential for future growth.
• The company's collaboration with Gilead could lead to further partnerships and opportunities.

Next Steps

• The company is targeting to initiate the IDE397 and Trodelvy Phase 1/2 combination expansion in MTAP-deletion urothelial cancer in Q4 2024.
• The company is enrolling a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Trodelvy in MTAP-deletion urothelial cancer patients.
• The company is focused on enrolling patients in the IDE397 Phase 2 monotherapy expansion in MTAP-deletion lung and bladder cancer.

Key Dates

Keywords

IDE397, MTAP-deletion, urothelial cancer, NSCLC, MAT2A inhibitor, clinical trial, cancer therapy, Trodelvy, ctDNA, oncology